Posted 3rd May 2018 by Jane Williams
The opportunity afforded by the microbiome for developing therapeutic and wellness products is matched only by the formidable task of unraveling the science of the microbiome in the first place. Microbiome research is transitioning from a descriptive to a more mechanistic science, and progress in understanding mechanisms that underpin microbiome biology is likely to result in a surge of interest in this space on the part of the biotech, pharma and investor communities.
Posted 14th September 2017 by Jane Williams
“We need a shift from correlation to causation to support further progress,” says Weizmann Institute of Science’s Eran Elinav, echoing a widely espoused sentiment in the microbiome space. “We spent the first decade finding associations of microbiota with different clinical indications, but now we are discovering that only some of these are phenotypes that are caused by changed microbiota,” adds Elinav who is also scientific co-founder of Israel-based BiomX and DayTwo.